Norway· NO-ID_02F05E56-EEBE-4C3E-945F-37B6E7017116
Stivarga
A regorafenib product containing regorafenib, registered in Norway by Bayer AG. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Regorafenib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX05 (regorafenib), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Regorafenib · ATC L01EX05
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of regorafenib costs, country by country.
Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Regorafenib · price per daily dose (0.12 g)
USD · FX 28 Sept 2026
- IT Italy$140.25
- CH Switzerland$139.52
The record
At a glance
FEST (Norway)- Active substance
- Regorafenib
- Manufacturer
- Bayer AG
- Country
- Norway (NO)
- ATC code
- L01EX05
- ATC class
- Regorafenib
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_02F05E56-EEBE-4C3E-945F-37B6E7017116
- no_varenummer4581493 x 28NOK 30238.8
- gtin7046264581490
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
248 interactions on record for regorafenib.
Graded by severity as the source publishes them — 116 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Regorafenib · interactions on record
248 records
- 116 severe
- 125 moderate
- 7 minor
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Regorafenib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandStivargaParanova Oy
- CzechiaSTIVARGABayer AG, Leverkusen
- SpainSTIVARGA 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULABayer Ag
- FranceSTIVARGA 40 mg, comprimé pelliculéBAYER AG (ALLEMAGNE)
- IrelandStivarga 40 mg film-coated tabletsBayer Pharma AG
- IcelandStivargaBayer AG*
- NetherlandsStivarga 40 mg, filmomhulde tabletBayer AG
- PolandStivargaBayer AG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Stivarga
- Liechtenstein · Stivarga
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/219c25d6-2c92-45d0-85fc-9db1b60672a2 GET /v1/drugs/219c25d6-2c92-45d0-85fc-9db1b60672a2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Regorafenib",
"merkevare_id": "ID_02F05E56-EEBE-4C3E-945F-37B6E7017116",
"name_form_strength": "Stivarga tab 40 mg",
"prescription_group": "C"
}See everything about regorafenib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.